

CLEARBRIDGE HEALTH LIMITED
(Incorporated in the Republic of Singapore)
(Company Registration No. 201001436C)

CORRIGENDUM – DISPOSAL OF SHARES IN BIOLIDICS LIMITED

The board of directors (the "**Board**" or the "**Directors**") of Clearbridge Health Limited (the "**Company**", and together with its subsidiaries, the "**Group**") refers to the announcement of the Company dated 21 July 2023 in relation to the disposal of its shares in Biolidics Limited ("**Disposal Announcement**"). All capitalised terms used and not defined in this announcement shall have the same meanings ascribed to them in the Disposal Announcement.

The Board wishes to clarify that the NTA as at 31 December 2022 prior to the disposal of such shares in Biolidics as set out in paragraph 7.2 of the Disposal Announcement should have been S\$20,707,000 instead of S\$23,141,000. The difference of S\$2,434,000 arose due to an oversight, which was only recently discovered, and relates to the non-controlling interests' goodwill resulting from the ownership of Clearbridge Medical Group Pte. Ltd. ("**CBMG**") by the preference shareholders of CBMG which should have been excluded in the computation of the NTA of the Group attributable to owners of the Company. Accordingly, paragraph 7.2 of the Disposal Announcement should read as follows, with the deletions in strikethrough and red, and the additions in bold and underline:

"The effect of the Disposal on the NTA of the Group is as follows:

	Before the Disposal	Upon completion of the Disposal
NTA as at 31 December 2022 (S\$'000)	23,141 <u>20,707</u>	22,989 <u>20,555</u>
Number of shares in issue	618,210,340	618,210,340
NTA per share (Singapore cents)	3.74 <u>3.35</u>	3.72 <u>3.32</u> ⁽¹⁾

Note:

- (1) Based on the Net Proceeds of approximately S\$930,000 and the NTA of the Sale Shares as of 31 December 2022 of approximately S\$1,082,000. The NTA of the Sale Shares as of 31 December 2022 is computed based on the Fair Value set out in paragraph 5.1 of this announcement."

Shareholders and potential investors are reminded to exercise caution when dealing in the securities of the Company and should consult their stockbrokers, bank managers, solicitors, accountants, or other professional advisers if they are in doubt about the actions that they should take.

BY ORDER OF THE BOARD

Yee Pinh Jeremy
Executive Director and Chief Executive Officer

22 September 2023

*This announcement has been prepared by the Company and has been reviewed by the Company's sponsor, United Overseas Bank Limited (the "**Sponsor**"), for compliance with Rules 226(2)(b) and 753(2) of the Singapore Exchange Securities Trading Limited ("**SGX-ST**") Listing Manual Section B: Rules of Catalist. This announcement has not been examined or approved by the SGX-ST. The SGX-ST assumes no responsibility for the contents of this announcement, including the correctness of any of the statements or opinions made or reports contained in this announcement. The contact person for the Sponsor is Mr David Tham, Senior Director, Equity Capital Markets, who can be contacted at 80 Raffles Place, #03-03 UOB Plaza 1, Singapore 048624, telephone: +65 6533 9898.*